Our unexpected findings thus extend the initial application of CDK4/6 inhibitors in treating estrogen receptor-positive (ER+) breast cancers which are often characterized with dysregulated CDK4/6 activation18–25, where the oncogenic addiction to cyclin D1 is being targeted. Here, CDK4 is linked to breast carcinoma.